Wo-mens Health

Memidis Pharma

Memidis Pharma is a family-owned pharmaceutical company founded in 2003. We create solutions for Women’s and Men’s Health. We offer solutions for men and women at all stages of their lives such as: menopause, pregnancy, fertility, contraception and sexology.

Partner in uro-gynaeology

What makes us unique?

Memidis has a diverse range of gynecological and urological products, tailored to patient needs. By sharing our knowledge and high-quality service, Memidis has developed into a valued partner within uro-gynecology.

In recent years, Memidis has marketed progressive treatments for indications such as: vaginal infections, vaginal atrophy, dyspareunia, recurrent urinary tract infections, erectile dysfunction and contraception.

By bringing these therapies to the market, Memidis Pharma is meeting the increasing needs of both patients and physicians. Factors that play an important role are: effectiveness, ease of administration, compliance, side effects and improvement of the patient’s quality of life.

Progressive

Success stories

In 2003, Memidis Pharma very successfully introduced the first non-hormonal treatment for vaginal atrophy Premeno. A hyaluronic acid-containing vaginal ovule and Hyalofemme a gel that also contains hyaluronic acid. Premeno and Hyalofemme are an excellent treatment for women who cannot or do not wish to use hormones. Hyalofemme and Premeno can also be used for vaginal dryness resulting from treatments for (breast) cancer.

In the field of vaginal infections, Normaflor vaginal tablets and Evagynal vaginal solution are important products for the treatment and prophylaxis of bacterial vaginosis. When introduced, this was a totally new method of treatment of a common and underestimated condition. Since then, Evagynal and Normaflor have become important products within gynecology.

Pre-Seed vaginal lubricant was introduced in 2007. Pre-Seed was a new development for couples with a desire to conceive, the first vaginal lubricant that is sperm safe. This drew attention in getting pregnant to the use of vaginal lubricants . Pre-Seed was further developed and entered the market as Prefert from 2015.

A new prophylaxis for recurrent urinary tract infections, Bacilac Femina, was introduced to the Dutch market in 2013. With the advent of Bacilac Femina, resistance to antibiotics can be reduced.

All these developments have brought Memidis Pharma a solid image in the urogynaecological world within the foreseeable future.

More effective than current treatment options

Contributing to quality of life

Fewer or no side effects

Increasing ease of use

Vision

Mission

Memidis Pharma aims to develop and/or market innovative “patient friendly” products for gynecological and urological indications. Memidis Pharma focuses on the underexposed indications with a large unmet medical need.

Memidis Pharma’s goal is to improve the well-being of patients of all age groups by making available therapeutic treatments that provide substantial clinical added value

Collaborate

Wholesalers we work with

Netherlands

Belgium